Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Actively Recruiting
About This Study
OK-TRANSPLANT 2 is a pragmatic, open-label vanguard study evaluating the feasibility of a weight loss intervention for patients with obesity and high-risk CKD or ESKD seeking kidney transplantation. Participants are randomized to receive either a virtual weight management program, which includes semaglutide and coaching, or standard of care. The study assesses recruitment feasibility, treatment adherence over 26 weeks, and the safety profile of GLP-1RA therapy in this specific population. The primary objective is to determine the viability of a larger multicenter trial aimed at reducing BMI-related barriers to transplant waitlisting.
Who Can Participate?
✓ Inclusion Criteria
- •Adults aged 18 years or older
- •BMI > 35 kg/m^2
- •>10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis
✗ Exclusion Criteria
- •Known contraindication to a GLP-1RA
- •Type 1 diabetes
- •No access to semaglutide via drug coverage
- •Absolute contraindication to kidney transplant
- •Pregnant, breastfeeding or planning to become pregnant